While our study has notable strengths, including a large, well-characterized clinical cohort at various stages of chronic kidney disease, state-of-the-art methods to characterize lipoprotein particles in plasma, and a novel mouse model to evaluate the effects of circulating liver-derived APOL1 on disease progression, it has numerous limitations. Here, APOL1 is linked to chronic kidney disease.